Sleep Disorder Therapeutics Market Set to Witness an Uptick During 2015 – 2021 : Persistence Market Research

Sleep disorders include a variety of complications related to sleep and have a high prevalence across the globe. Based on these complications, sleep disorders can be classified into three categories- lack of sleep which includes insomnia, excessive sleep which includes narcolepsy and disturbed sleep which include sleep apnea and Rapid eye movement (REM) disorder. Insomnia may arise as result of unhealthy diet, emotional dreams, stress, and many other factors. Insomnia may affect reaction time towards common stimulus, hand-eye coordination, memory, and disturb daily life. Narcolepsy is a disorder that causes uncontrolled sleep at time period lasting less than minute or more than an hour. It has also been found that patients with narcolepsy experience sleep attacks more often during pregnancy, stress or ill health. Usually narcolepsy is a genetic disease, but it has also been found to develop as a result of some neurological disorders or severe brain damage. REM sleep behavior disorder involves abnormal behavior in sleep. In this disorder, a patient dreaming about running, may run while still asleep. Sleep apnea is obstructed breathing during sleep.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/5714

According to a press release in March 2014 by World Association of Sleep Medicine, 45% of the global population suffers from some form of sleep disorder. It also mentions that approximately 25% male and 10% females in the U.S. suffer from sleep apnea. This high prevalence suggests an opportunity for a large therapeutics market.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/5714

Currently marketed drugs include Sanofi-Aventis manufactured Ambien (zolpidem), Sunovion Pharmaceuticals Inc.’s Lunesta (eszopiclone), Takeda Pharmaceutical’s Rozerem (ramelteon), Somaxon Pharmaceuticals, Inc.’s Silenor (doxepine) and various others. Over-the-counter drugs are also available for treating sleep disorder; these include Nytol, Sominex, Compoz, and Unisom. Merck’s Suvorexant drug is an orexin receptor agonist which is under Phase III trial. Other companies involved in the drug development of sleep disorder include Vanda Pharmaceuticals, Eli Lilly, GlaxoSmithKline and Neurim Pharmaceuticals.

To Know About Latest Report Click Here: http://www.persistencemarketresearch.com/market-research/sleep-disorder-therapeutics-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.